Bicara Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
116 Huntington Ave Ste 703, Boston, Mass...Phone Number
(617) 468-4219Website
www.bicara.comRevenue
-Stock Symbol
BCAXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Bicara Therapeutics
Bicara Therapeutics is focused on combating cancer by merging targeted therapies with tumor-microenvironment modulators to develop more effective medicines for patients. The company aims to improve treatment options for individuals affected by cancer. Their innovative approach leverages scientific advancements to address the complexities of tumor biology. Bicara Therapeutics is dedicated to transforming the landscape of cancer treatment.Explore more
Bicara Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bicara Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Bicara Therapeutics is spiking on competitors!
Earning: See what the market has to say on Bicara Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Bicara Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Bicara Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Bicara Therapeutics
Check if Bicara Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Bicara Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Bicara Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Bicara Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Bicara Therapeutics
Compare insights from companies similar to Bicara Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bicara Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Bicara Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bicara Therapeutics.
Bicara Therapeutics financials insights
Gather financial insights about Bicara Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series B
$108M
Series C
$165M
2024
Stock Offering
$315M
Bicara Therapeutics Tech Stack
A closer look at the technologies used by Bicara Therapeutics
Most Recent Scoops
Person-Based
Pharmaceuticals
Person-Based
Open Position
Open Position
Open Position
Bicara Therapeutics News & Media
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the appointments of Jeremy Bender, Ph.D., MBA and Christy Oliger to its Board of Directors. Dr. Bender, who most recently served as Chief Executive Officer at Day One Biopharmaceuticals through its acquisition by Servier in 2026, brings more than 20 years of corporatBicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on July 1, 2026 to four new employees under Bicara’s 2026 Inducement Plan as a material inducement to employment.What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
This Boston-based biotech, focused on bifunctional antibody therapies for cancer, just reported a notable insider sale in recent filings.Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bicara Therapeutics
Sign Up For FreeTo access detailed company insights
Bicara Therapeutics is focused on combating cancer by merging targeted therapies with tumor-microenvironment modulators to develop more effective medicines for patients. The company aims to improve treatment options for individuals affected by cancer. Their innovative approach leverages scientific advancements to address the complexities of tumor b... Read More
